Using repeated 10-fold cross-validation, patients could be classified into prostate cancer and cancer-free groups based on their PSA levels with mean accuracies of 62% and 64%, using Random Forest and Linear Discriminant Analysis, respectively (Table 3). The gene discussed is KLK3; the disease is prostate carcinoma.